In Brief
INTRODUCTION
The purine nucleoside, adenosine, is a vital cytoprotective molecule mediating effects through activation of four subtypes of Class A G-protein-coupled receptors (GPCRs), the A 1 , A 2A , A 2B , and A 3 adenosine receptors (ARs) (Fredholm et al., 2011) . Given the broad distribution of ARs in the central nervous system and the periphery, strategies for enhancing or inhibiting the activity of ARs have been pursued for potential treatments of disorders associated with cardiovascular function, blood flow, anxiety, dementia, Parkinson's disease, pain, respiration, sleep, inflammation, and immunity (Jacobson and Gao, 2006) . Nonetheless, very few AR drug candidates have successfully progressed through clinical trials. One reason for this failure is the widespread distribution of ARs. If a drug candidate has insufficient selectivity for a given AR subtype, then the potential exists for off-target side-effects (Chen et al., 2013) . Even when appropriate selectivity can be achieved, a second reason for drug candidate failures is that, like most GPCRs, ARs couple to multiple signaling pathways and can thus mediate both beneficial and undesirable effects, depending on the pathway.
In this regard, the A 1 -AR is a key model for addressing these challenges. For instance, A 1 -AR activation can reduce cardiac and renal ischemia reperfusion injury, atrial fibrillation, and neuropathic pain (Jacobson and Gao, 2006) , whereas inhibition of A 1 -ARs may prove useful for developing potassium sparing diuretics or cognition enhancers (Mü ller and Jacobson, 2011) . However, clinical trials of A 1 -AR selective agonists for ischemic heart disease have failed predominantly due to dose-limiting on-target bradycardia, atrioventricular block, and hypotension (Braunwald, 2011; Kloner et al., 2006; Mustafa et al., 2009) , while the A 1 -AR antagonist, rolofylline, developed as a diuretic for patients with acute heart failure and caused off-target stroke and on-target seizures (Massie et al., 2010; Teerlink et al., 2012) Alternative paths are thus required for improving drug action at the A 1 -AR. One approach is to selectively target allosteric sites, which are spatially distinct from the orthosteric site and can also promote conformational states that emphasize beneficial signaling while minimizing on-target adverse effects-a phenomenon referred to as ''biased agonism'' (Changeux and Christopoulos, 2016; Kenakin and Christopoulos, 2013) . Indeed, the A 1 -AR possesses at least one allosteric site ) that has been exploited to promote biased agonism (Valant et al., 2014) . However, despite mutational analyses implicating the extracellular regions of the A 1 -AR in allosteric modulator action (Kennedy et al., 2014; Nguyen et al., 2016b; Peeters et al., 2012) , the precise location of this site remains undetermined, as do mechanisms underlying A 1 -AR allostery. A second major avenue for improving GPCR drug selectivity is to exploit recent breakthroughs in structural biology that may guide structure-based drug design (Jazayeri et al., 2015) .
Despite these exciting developments, the only high-resolution information available for the ARs comes from structures of the A 2A -AR (Carpenter et al., 2016; Congreve et al., 2012; Doré et al., 2011; Hino et al., 2012; Jaakola et al., 2008; Lebon et al., 2015 Lebon et al., , 2011 Liu et al., 2012; Segala et al., 2016; Xu et al., 2011) . Unfortunately, the low sequence identity between A 2A -and A 1 -ARs, especially in the extracellular loops, makes homology modeling of this region unreliable. In contrast, there exists a very high conservation of residues between the A 1 -and A 2A -ARs in the orthosteric site, yet this fact is difficult to reconcile with the known array of subtype-selective agonists and antagonists that have been reported for these receptors.
Here, we present the high-resolution crystal structure of the A 1 -AR in complex with a covalent antagonist, DU172 (originally published as 'compound 23a' in Beauglehole et al., 2000) . Compared to the A 2A -AR, the A 1 -AR possesses a more open binding site cavity that can accommodate orthosteric and allosteric ligands. We propose that spatial differences due to rearrangements of TMs 1, 2, 3, 7, ECL3, and a single amino acid substitution at position 270, rather than specific differences in residues lining the orthosteric binding pocket, underlie drug selectivity between A 1 -and A 2A -ARs and offer an alternative template for AR structure-based drug design.
RESULTS

Optimization of A 1 -AR Crystallization Constructs and Ligand Selection
To aid with A 1 -AR expression, 22 amino acids of the human M 4 muscarinic acetylcholine receptor N terminus, containing 3 N-glycosylation sites, were inserted before the A 1 -AR N terminus, followed by a 3C protease cleavage site ( Figure 1A ). To promote A 1 -AR crystallization, a thermostable apocytochrome b 562 RIL (BRIL) was inserted into the third intracellular loop 3 (ICL3) between residues 211 and 220 (all numbering is relative to the unmodified human A 1 -AR: ''A 1wt -AR''); the A 1 -AR C terminus was truncated after amino acid 311 by inserting a 3C protease cleavage site, and a single A 1 -AR N-glycosylated residue, N159, was mutated to alanine. For optimization of the BRIL insertion sites, we also substituted amino acids 220-228 of the A 1 -AR with those of the A 2A -AR. (D) Receptor-mediated ERK1/2 phosphorylation of the different A 1 -AR constructs in the presence of the agonists NECA or R-PIA. Data points are the mean values ± SEM from three-four independent experiments performed in duplicate. See also Tables S1 and S2. Importantly, unmodified A 1wt , ''A 1expr '' (before 3C cleavage), and ''A 1cryst '' (crystallized construct) showed no difference in binding affinities for the A 1 -AR antagonist DPCPX or the irreversible antagonist DU172 (Figures 1B, 1C, S1, and Table S1 ), although A 1cryst displayed a lower B max , most likely reflecting variability in the transient transfections used for these experiments. As noted previously with T4 lysozyme fusions of the A 2A -AR or b 2 adrenergic receptors (Jaakola et al., 2008; Rosenbaum et al., 2007) , the engineered A 1 -AR constructs exhibited higher affinity for agonists, in this instance, NECA and R-PIA ( Figure 1C and Table S2 ). However, consistent with findings at the A 2A -AR , BRIL insertion into the A 1 -AR ICL3 prevented G protein coupling, resulting in no functional response ( Figure 1D ). Subsequently, we tested a variety of non-and subtype-selective AR agonists and antagonists for their ability to increase the melting temperature (T m ) of the A 1 -AR in a thermal stability assay ( Figure S2 ) (Alexandrov et al., 2008) . Among all the ligands tested, only highly selective A 1 -AR antagonists substantially increased the stability of the A 1 -AR construct used for crystallization. The covalent compounds, FSCPX and DU172, promoted the largest increase in thermal stability ($16 C) , and due to the higher chemical stability of DU172 compared to FSCPX (Beauglehole et al., 2000) , DU172 was used in all subsequent crystallization trials.
Overall Structural Organization of the A 1 -AR$DU172 Complex
The A 1 -AR$DU172 complex was crystallized in a lipid cubic phase. Data from 29 crystals were merged together, yielding a dataset at 3.2 Å resolution (Figures 2 and S3 and Table S3 ). The A 1 -AR crystallized with two receptor copies per asymmetric unit in parallel orientations ( Figure S3 ). Overall, electron density maps were of good quality with well-resolved amino acid side chains, with the exception of poor density around BRIL in chain A. Interestingly, we noted two types of receptor-receptor interfaces ( Figure 3 ). The first was a non-crystallographic 2-fold symmetry interface ( Figures 3A, 3B , S3A, and S3C) stabilized through contacts at the extracellular side of TM3 through a p-p interaction between two Y76 3.21 residues in chains A and B, an interaction between two H78 3.23 residues (superscript refers to Ballesteros-Weinstein numbering [Ballesteros and Weinstein, 1995] Figure 3D ). Interestingly, a recent mutagenesis study (Nguyen et al., 2016a) identified resides of the A 1 AR ECL2 (N148, E153, S150, R154, and W156) to be key determinants in the signaling efficacy of the orthosteric agonist, NECA. Our structure now reveals that all of these residues are located in the A 1 -AR ECL2 helical region, with R154 and S150 in particular ( Figure 3D ) forming contacts between ECL2 loops of two A 1 AR monomers. This finding provides a possible structural explanation for why these residues are key to agonist efficacy, particularly in the context of an emerging view that ECL2 can contribute to the transition of GPCRs between different active states (Avlani et al., 2007; Bokoch et al., 2010) . Collectively, and in light of another recent study suggesting that the A 1 -AR could form homodimers capable of cooperative orthosteric ligand binding (Gracia et al., 2013) , this interface is an attractive target for future investigation, but additional pharmacological experiments will be required to confirm that observed interaction is physiologically relevant rather than an artifact of crystallization.
Overall, the structure of the A 1 -AR is typical of other Class A GPCRs crystallized in an inactive conformation (Figures 2A and  2C ) with a partially formed ''ionic lock'' ( Figure S4 ) that constrains GPCRs in an inactive state and may thus explain why the A 1 -AR displays relatively low constitutive activity (Savinainen et al., 2003) . There is little difference intracellularly, with the exception of a 2 Å outward shift of TM5 and TM6 at the BRIL insertion site Table S3. due to crystal contacts ( Figure 2C ). However, the extracellular ends of the TM helices move considerably compared to the A 2A -AR ( Figure 2B ), with lateral movements of TMs 1, 2, 3, and 7. A highly conserved Class A GPCR disulphide bond (C80 3.25 and C169) tethers ECL2 to TM3 ( Figure 2D ), and an additional disulphide, C260-C263 ( Figure 2B ), present in both A 1 -and A 2A -ARs, ''staples'' ECL3. The compact arrangement of the TM bundle of the A 2A -AR might thus be the result of its unique disulphide bond, C74-C146, tethering the beginning of TM3 to the end of ECL2 ( Figure 2D ). Lack of this interaction in the A 1 -AR allows for shifts in TMs 1, 2, and 3. TM7 also tilts toward TM6, possibly as a result of a shorter ECL3 in the A 1 -AR due to the deletion of one amino acid.
The most striking difference between the A 1 -and A 2A -ARs is the conformation of their ECL2s ( Figure 2D ). In both chains A and B of the A 1 -AR, ECL2 is well resolved and adopts an identical orientation despite different crystallographic environments, indicating that the observed loop conformation is not a crystallographic artifact nor is it influenced by the location of the BRIL fusion (which is more than 10 Å away). Of note, ECL2 residues from N148 to S161 form a longer helix compared to the A 2A -AR (from K150 to G158) ( Figure 2E ), extending it away from the A 1 -AR transmembrane regions and almost perpendicular to the plane of the membrane ( Figure 2D ). This conformation likely results from the absence of another A 2A -AR disulphide bond (between C71 and C159) in the A 1 -AR, which tethers the A 2A -AR ECL2 helix to ECL1. Instead, it is partially compensated for by the presence of a salt bridge between E164 and H78 3.24 on TM3 in the A 1 -AR, which stabilizes a short b sheet between amino acids 75-77 of ECL1 and 165-167 of ECL2 ( Figure 2D ). Interestingly, the helical part of ECL2 in previously solved b 1 and b 2 adrenergic receptors also adopts a conformation parallel to the plane of the membrane due to intra-loop disulphides. As such, the presence of extra disulphide bonds likely serves to restrict the mobility of ECL2 in b 1 , b 2 , and A 2A receptors, whereas this is not the case for the A 1 -AR.
Ligand Interactions in the A 1 -AR Orthosteric Site The electron density for the covalent antagonist, DU172, allowed for its unambiguous placement within the binding site of the A 1 -AR and identified Y271
7.36 as the site of covalent attachment via a benzenesulfonate linkage ( Figure 4A and Figure S5 ). Key interactions with the ligand are formed via residues located on TMs 1, 3, 6, 7, and ECL2 ( Figure 4C ). Compared to the orientation of ZM241385 in A 2A -AR structures (Hino et al., 2012; Jaakola et al., 2008; Liu et al., 2012) , the xanthine ring of DU172 is rotated by 135 (Figure 4B ), positioning the propyl group above W247 6.48 , a residue responsible for TM rearrangements during A 2A -AR agonist binding (Xu et al., 2011 6.55 contacts the oxygen of the furan ring and the amine substituent of the triazine ring of ZM241385; the corresponding N254 6.55 in A 1 -AR interacts with the 6-oxy group and N7 of the DU172 xanthine ring ( Figure 4B ). This H-bonding shift results in DU172 positioning deeper in the A 1 -AR orthosteric site compared to ZM241385 in the A 2A -AR. DU172 is further stabilized by an H bond of the amide linker with Y12 1.35 , which can explain why DU172-like FSCPX derivatives, in which the amide linker was exchanged to two methylenes, display lower affinity for the A 1 -AR (Beauglehole et al., 2000) . In addition, many A 1 -AR residues interact with DU172 via hydrophobic interactions ( Figure 4E and S5). 5E ). In the structures of a non-thermostabilized A 2A -AR (Hino et al., 2012; Jaakola et al., 2008; Liu et al., 2012) , ZM241385 adopts an extended conformation and binds perpendicularly to the plane of the membrane ( Figures 5C and 5D ). In contrast, the bulky substituents in the 3-and 8-positions of the xanthine core of DU172 are accommodated laterally, engaging both sides of the wide binding cavity (Figures 5A and 5B).
In addition to the substantial effect of overall binding site topology on A 1 -AR versus A 2A -AR selectivity, the hydrophobic pocket responsible for engaging the cyclohexane group of DU172 (and likely other cyclic groups found in the C8 position of A 1 -AR selective antagonists) is inaccessible in the A 2A -AR due to a single amino acid difference in position 270 7.35 .
This residue acts as a ''gatekeeper,'' either allowing access to residues M177 5.35 , L253 6.54 , and T257 6.57 in the A 1 -AR, where amino acid 270 is a threonine, or limiting access in the A 2A -AR, where bulky methionine points into the binding pocket ( Figure 5E ). This residue is also variable in the A 1 -AR of different species, leading to significant effects on the affinity of A 1 -AR ligands (Tucker et al., 1994) . Therefore, to test the hypothesis that residue 270 7.35 can contribute to subtype selectivity, we performed mutagenesis experiments that swapped the residues in this position between the A 1 -and A 2A -ARs (Figures 5F and 5G). As predicted, T270M substitution into the A 1 -AR significantly decreased the affinity of DPCPX (Figure 5H and Table S4 ), while the reverse substitution, M270T in the A 2A -AR, led to a significant increase in DPCPX affinity (Figure 5H and Table S4 ). As ZM241385 lacks substituents capable of engaging the aforementioned hydrophobic pocket of the A 1 -AR, T270M substitution has little effect on the affinity of this ligand ( Figure 5H and Table S4 ). However, since M270 is involved in coordinating ZM241385 in the A 2A -AR, M270T leads to a significant loss of affinity ( Figure 5H and Table S4 ). A further expansion of the A 1 -AR binding site results from a 3.5 Å movement of ECL3 away from the orthosteric pocket ( Figure 5E ). This leads to inability of the A 1 -AR to form a salt bridge between ECL2 and ECL3 observed in most A 2A -AR structures (H264-E169). Interestingly, in most A 2A -AR crystal structures published to date (Congreve et al., 2012; Doré et al., 2011; Hino et al., 2012; Jaakola et al., 2008; Lebon et al., 2015 Lebon et al., , 2011 Liu et al., 2012; Segala et al., 2016) , ECL3 brings H264 within the range for salt bridge formation with E169. The status of the H264-E169 interaction can also affect ligand residence time for the A 2A -AR, as compounds that stabilize it exhibit slower dissociation rates (Segala et al., 2016) . The 8-cyclohexyl-1-propylxanthine moiety of DU172 is very similar to DPCPX, a compound with a short t 1/2 (May et al., 2005) , and the broken bridge between H264 and E172 in our A 1 -AR structure ( Figure 5E ) is a possible molecular mechanism that can explain such faster kinetics. Given that ligand residence time has emerged as a major consideration in modern drug discovery programs (Copeland et al., 2006; Guo et al., 2016a Guo et al., , 2016b Segala et al., 2016) , a molecular understanding of the basis of the phenomenon will play an important role in guiding future structure-based drug design programs.
In contrast to the key role of hydrophobic interactions in the pocket formed by residues M177 5.35 , L253 6.54 , and T257 6.57 in the A 1 -AR, high binding affinity for selective A 2A -AR ligands is mediated through the narrow entrance into its binding site (Figures 5C and 5D) . Tight arrangement of the TM bundle, enforced by the extra disulphide bond (from C74 to C146) of the A 2A -AR, brings L267 7.32 , important for receptor affinity (Lebon et al., 2015) , within van der Waals distance from the phenyl ring of ZM241385 (Figures 4D and 4F) and other ligands with similar scaffolds (Segala et al., 2016) . The 3.5 Å outward movement of the extracellular part of TM7 that we observe in our A 1 -AR structure ( Figure 2B ) would prevent this interaction. Thus, it is evident that the spatial differences in the A 1 -and A 2A -AR orthosteric sites are the major determinants underlying the subtype selectivity of their respective compounds. To confirm that the wide A 1 -AR binding pocket was not an artifact of the covalent attachment by DU172 and to investigate whether other A 1 -AR selective antagonists share this pocket, we performed additional experiments. First, we synthesized the novel, reversible sulfonic acid (MIPS2712) and N, N-dimethylsulfonamide (MIPS2719) analogs of DU172 ( Figure S1 ), which exhibited even higher selectivity for the A 1 -over the A 2A -AR compared to the irreversible DU172 ( Figures S6A-S6C ). Molecular docking of both compounds using ICM revealed similar modes of binding to DU172 in the A 1 -AR structure, which cannot be accommodated by the narrow binding site of the A 2A -AR, as it prevents their xanthine cores from entering and interacting with N253 6.55 or F171 ( Figures S6D and S6E ). Second, we investigated whether other, less bulky, A 1 -AR selective antagonists shared the same binding pocket by performing additional computational docking ( Figure 6 and Table S5 ). Most reversible A 1 -AR antagonists, including DPCPX, PSB36, and the clinical agent rolofylline have a scaffold similar to DU172 ( Figure S1 ). Our docking predicted a common binding site for all of these compounds ( Figures 6A-C) . Third, molecular dynamics simulations of DPCPX bound to the A 1 -AR over a 104 ns timescale further confirmed stable conformations of both ligand and receptor, with no change or collapse of the wide binding cavity (Figures S6F-S6H) . One exception from a xanthine-based selective A 1 -AR scaffold is SLV320 ( Figure S1 ). When docked into the Table S4. A 1 -AR, the pyrrolopyrimidine core assumes a topologically similar orientation to the xanthine cores of other compounds, which position the aminocyclohexanol group within van der Waals distance from V87 3.32 , H278 7.43 , and V62 2.57 , and H-bonding distance from the carbonyl of V62 2.57 . As such, instead of exploring the hydrophobic pocket near T270, like other selective A 1 -AR antagonists, SLV320 engages the other side of the wide binding site of the A 1 -AR ( Figure 6D ).
Location of a Secondary Pocket in the A 1 -AR
The A 1 -AR is the first GPCR for which synthetic small molecule positive allosteric modulators (PAMs) of orthosteric agonists were described . In contrast, far fewer reports have described A 2A -AR modulators (Gö blyö s and IJzerman, 2011; Guo et al., 2016b) . These findings may be explained by the substantial differences when comparing the extracellular surfaces of the A 1 -AR versus the A 2A -AR. Indeed, recent mutagenesis studies have suggested a role for ECL2 in the actions of A 1 -AR allosteric modulators (Kennedy et al., 2014; Nguyen et al., 2016b; Peeters et al., 2012) . Another intriguing property of many A 1 -AR modulators, exemplified by VCP171 ( Figure S1 ) and related derivatives, is the fact that they invariably act as PAMs of orthosteric agonists of the receptor, but as inhibitors of orthosteric antagonists at the same receptor Kourounakis et al., 2000; van der Klein et al., 1999) . One possible explanation for this finding is that modulators of this class bind to a spatially distinct allosteric site in the inactive state that promotes negative cooperativity with antagonists (thus acting as negative allosteric modulators, or NAMs), while stabilizing a different conformation in the active state that yields positive cooperativity with agonists-as has been observed, for instance, with the muscarinic acetylcholine GPCRs (Dror et al., 2013; Kruse et al., 2013) . However, an alternative explanation is that A 1 -AR modulators actually bind to the orthosteric site in the unoccupied (inactive) receptor, thus essentially acting as ''competitive'' antagonists, and adopt a second, allosteric, binding mode only when the receptor's orthosteric site is occupied by an agonist in the active state.
Given that we established that the wide extracellular A 1 -AR cavity is not an artifact of the covalent attachment by DU172, it is of note that part of this cavity is engaged in binding of the linker and the irreversible group of DU172. However, when less bulky prototypical reversible orthosteric antagonists, such as DPCPX, are docked into the A 1 -AR, a significant part of the binding site is left un-accommodated, in contrast to the binding cavity of the A 2A -AR occupied by ZM241385 (Figures 7A and 7B ). This unaccommodated secondary pocket may thus represent a putative allosteric binding site in the inactive-state A 1 -AR or may contribute to the formation of such a site upon activation of the receptor. To investigate possible mechanisms underlying the behaviors of known A 1 -AR allosteric ligands described above, we performed computational docking of VCP171 (Aurelio et al., 2009; Valant et al., 2014) and compound 13b (Ferguson et al., 2008) (Figures S1 and S7) . Although both compounds inhibit the binding of the antagonist, [ 3 H]DPCPX (Ferguson et al., 2008; Nguyen et al., 2016b) , VCP171 is a PAM of agonist binding and function (Nguyen et al., 2016b) , while compound 13b exerts highly potent inhibitory effects on both agonists and antagonists, despite being able to slow the dissociation of a radiolabeled orthosteric agonist when tested at high concentrations (Ferguson et al., 2008) ; the latter is usually a hallmark of an allosteric interaction. Interestingly, we found that, in both instances, the ligands preferred to dock in the orthosteric site on the unoccupied A 1 -AR structure ( Figures 7C and 7D ) utilizing similar binding interactions as DU172 ( Figure S7 ). Taken together, the finding that different types of A 1 -AR modulators prefer to occupy the orthosteric site in the inactive A 1 -AR can explain the long-standing conundrum of why such classes of ''allosteric'' ligand consistently behave as apparent competitive inhibitors of A 1 -AR antagonists such as DPCPX (Aurelio et al., 2009; Valant et al., 2014) , which preferentially bind to the inactive state. This also suggests that, mechanistically, it may be the transition between the inactive to the active state in the agonist-occupied receptor that changes the conformation of both the orthosteric and secondary pocket to yield an ''optimal'' allosteric site that allows positive agonist modulation by ligands such as VCP171, although this remains speculative in the absence of an active A 1 -AR structure bound to agonist, PAM, or both.
DISCUSSION
The A 1 -AR remains a highly pursued therapeutic target (Fredholm et al., 2011; Jacobson and Gao, 2006 ), yet there are no selective, clinically approved, A 1 -AR agonists or antagonists currently available. Nonetheless, numerous attempts have been made to develop selective ligands of this important GPCR, including structure-activity studies focusing on orthosteric ligands, allosteric modulators, and, more recently, hybrid ''bitopic'' molecules that concomitantly target both orthosteric and allosteric sites (Guo et al., 2016b) . To date, however, it has not been possible to contextualize any of these advances at the molecular level. Our solution of the crystal structure of this receptor can now facilitate structure-based drug design of A 1 -AR therapeutics. Despite sharing general mechanisms of function with the Class A GPCR superfamily, our structure more importantly reveals surprising differences that can account for the molecular basis of AR subtype selectivity and sheds light on some long-standing questions regarding the actions of allosteric modulators.
The solution of multiple crystal structures of the A 2A -AR has yielded insights into mechanisms of receptor activation, ligand binding, and modulation by endogenous substances such as sodium ions (Doré et al., 2011; Hino et al., 2012; Jaakola et al., 2008; Lebon et al., 2011; Liu et al., 2012; Xu et al., 2011) , in addition to facilitating structure-based drug design (Gutié rrez-deTerá n et al., 2017). Yet, it is well-established that even subtle differences between related GPCRs can have a profound effect on drug selectivity Manglik et al., 2012; Thal et al., 2016) , which is of particular relevance when trying to use previously solved GPCR structures to model or screen for new leads at other receptors. From a structural perspective, our A 1 -AR structure displays many of the key features associated with inactive-state GPCRs, including a well-resolved ''ionic lock'' that plays a vital role in maintaining the ground state of the receptor. From a pharmacological and chemical perspective, however, the most surprising feature is the divergence observed in the extracellular regions, particularly the differences in ECL2 orientation when comparing the A 1 -with the A 2A -AR. In combination with the ''gatekeeper'' role of residue 270 7.35 in these structures, the overall changes in the extracellular regions have a profound effect on the entrance and definition of the binding pocket between the two AR subtypes, thus providing a molecular mechanism for orthosteric ligand subtype selectivity.
The extracellular regions of various Class A GPCRs, including the A 1 -and A 3 -ARs, the muscarinic, adrenergic, and dopaminergic receptors, have also been implicated in the binding of synthetic small molecule allosteric modulators (Guo et al., 2016b; Kruse et al., 2013) . To date, however, only the active-state structure of the M 2 muscarinic acetylcholine receptor bound to an agonist and a PAM has been solved ( Kruse et al., 2013) . The location of the allosteric site(s) for synthetic modulators at the A 1 -AR remains unknown but has been inferred to involve the extracellular domains (Kennedy et al., 2014; Nguyen et al., 2016b; Peeters et al., 2012) . Our atomic resolution of these regions now raises a number of interesting considerations. The first is the presence of a secondary pocket in the A 1 -AR that is not observed in the A 2A -AR due to the more open arrangement of the extracellular domains of the former receptor. A second consideration, based on our modeling, is that ligands previously classed as ''allosteric modulators'' of the A 1 -AR may actually prefer to interact with the orthosteric site in the unoccupied (inactive) receptor. This finding can explain the long-standing conundrum that most A 1 -AR PAMs of orthosteric agonists actually behave as inhibitors of orthosteric antagonists Kourounakis et al., 2000; van der Klein et al., 1999) . Finally, albeit speculatively, we hypothesize that the TM regions of the A 3 -AR, which are more homologous to the A 1 -AR, can potentially adopt an ''open'' orientation like the A 1 -AR, which may explain the fact that numerous A 3 -AR allosteric modulators have also been identified relative to the paucity of allosteric ligands for A 2A -AR (Guo et al., 2016b) .
Taken together, our findings provide important insights into a highly valued GPCR target. In addition to revealing the molecular basis of subtype selectivity, our structure can potentially explain the differential effects that A 1 -AR allosteric ligands display against agonists versus antagonists and can even be used as an ''anti-target'' for screening of A 2A -AR selective antagonists currently in clinical development for Parkinson's disease (Pinna, 2014) and cancer immunotherapy (Leone et al., 2015) .
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
METHODS DETAILS
Expression and purification Our initial construct for the A 1 -AR expression, containing a HA signal sequence, N-terminal Flag tag, followed by a 3C protease cleavage site, and a C-terminal 8xHis tag expressed poorly. Thus, 22 amino acids of the M 4 muscarinic receptor, with 3 N-glycosylation sites, were added at the N terminus before a 3C-protease cleavage site, which increased receptor expression levels several fold. Generally, the addition of the M 4 N terminus increased the B max in saturation binding experiments from 1.7-3 nmol/L to 19-27 nmol/L in Sf9 cells, as well as the actual protein yield in test purification experiments (from less than 70 mg/L to 200-400 mg/L of culture for different constructs). We inserted an additional 3C site at the C terminus, after amino acid 311, substituted ICL3 (amino 211-220) with b 562 RIL (BRIL), and made an N159A substitution to promote crystallization. Though this construct yielded crystals, the diffraction quality was poor and we reasoned that optimization of the BRIL insertion site was required. Consequently, the first 8 amino acids of TM6, immediate to the C-terminal BRIL insertion site, were changed to corresponding residues of the A 2A -AR. The resulting construct was cloned into a pVL1392 vector, followed by expression in Sf9 cells using the Best-Bac Baculovirus expression system (Expression Systems). Cells were infected at 4x10 6 cells/ml and harvested 62 hr later. Due to the presence of adenosine in the media, no ligand addition was necessary.
All purification steps were performed in the presence of 0.2 mM DU172. Insect cells were lysed by osmotic shock in the buffer containing 10 mM Tris pH 7.5, 1 mM EDTA, 1 mM MgCl 2 , 1 mg/mL iodoacetamide with benzonase and protease inhibitors. Cell membranes were solubilized in solubilization buffer (30 mM HEPES pH 7.5, 1% dodecyl maltoside (DDM), 0.03% cholesterol hemisuccinate (CHS), 750 mM NaCl, 30% glycerol, 1 mM MgCl 2 , 1 mg/mL iodoacetamide with benzonase and protease inhibitors) for 2 hr at 4 C, spun down from insoluble debris and batch-bound to Ni-chelating resin for 1.5 hr at 4 C. Ni resin was then loaded on a glass column and washed by gravity flow using Ni-wash buffer (30 mM HEPES pH 7.5, 0.1% DDM, 0.003% cholesterol, 750 mM NaCl, 30% glycerol and 5 mM imidazole). Receptor was eluted in the wash buffer with 250 mM imidazole, supplemented with 2 mM CaCl 2 and then loaded onto an anti-Flag M1 antibody column at a flow rate of 1 ml/min. Detergent was exchanged into 30 mM HEPES pH 7.5, 0.1% lauryl maltose neopentyl glycol (MNG), 0.01% CHS, 100 mM NaCl, 2 mM CaCl 2 over the course of 1 hr. The final wash was done using 10xCMC buffer (30 mM HEPES pH 7.5, 0.01% MNG, 0.001% CHS, 100 mM NaCl) supplemented with 2 mM CaCl 2 , followed by elution into 10xCMC buffer with 10 mM EDTA and 0.2 mg/ml of FLAG peptide. Digest with 3C protease (1:7 w/w) was carried out overnight at 4 C in the presence of 22 mM DU172. Size-exclusion chromatography was performed using Superdex S200 Increase column in 10xCMC buffer. Monodispersed receptor fractions were pooled together, supplemented with 200 mM DU172 and concentrated to an A 280 of 84 and flash frozen in liquid N 2 in single-use aliquots.
Crystallization A 1 -AR was reconstituted into the lipid cubic phase by mixing it with a 10:1 monoolein:cholesterol (Hampton and Anatrace) mixture at 1:1.5 (w/w) ratio. Approximately 100 cycles of mixing were performed at 2 ml/sec using a Gryphon LCP mixing platform (Art Robbins Instruments). LCP crystallization was performed in siliconized 96-well plates overlaying 30 nL protein solution drops with 0.6 ml of well solution using the Gryphon LCP. Sealed glass plates were incubated at 20 C for 1-2 weeks. The best diffracting crystals grew in 100 mM HEPES pH 7.0-8.0, 28%-38% PEG 300 and 500-700 mM NH 4 F. For data collection whole drops were harvested using mesh grid loops (Mitegen) and flash frozen in liquid N 2 .
Data collection, processing & structure determination Diffraction data were collected at the MX2 beamline on an ADSC Quantum detector at the Australian synchrotron. Rastering and data collection was done at 13 keV with unattenuated beam collimated to 20x70 mm, using 1 s exposure per 1 oscillation in 5-10 wedges from each crystal. Data from 51 crystals were processed with XDS (Kabsch, 2010), analyzed using BLEND (Foadi et al., 2013) and the best datasets from 29 crystals were scaled and merged using Aimless (Evans and Murshudov, 2013) . Phaser (McCoy et al., 2007) was used to find an initial solution using an A 1 -AR homology model built by SWISS-MODEL as a template using an A 2A -AR crystal structure (PDB: 4EIY) . Refinement was carried out in Refmac5 (Murshudov et al., 2011) , and manual rebuilding was done using Coot (Emsley et al., 2010) . Model validation was performed using Molprobity (Chen et al., 2010) . All structure-related figures were prepared in PyMOL Molecular Graphics System, Version 1.7.2.1 (Schrö dinger, LLC).
Pharmacology
Pharmacological characterization of the A 1 -AR constructs was carried out in transiently transfected FlpIn Chinese hamster ovary (FlpIn CHO) cells. Constructs, A 1expr -, A 1cryst -, A 1(wt) -, A 1(T270M) -, A 2A(wt) -and A 2A(M270T) -AR were cloned into a pcDNA3.1 vector for transient transfection. A 1expr contained the full sequence of the construct expressed in Sf9 insect cells for crystallization. A 1cryst was truncated at 3C protease cleavage sites (with an added methionine at the N terminus) and was equivalent to the crystallized construct. Transient transfection with pcDNA3.1 was carried out in suspension before plating cells into 96-well plates using 100 ng of DNA and 600 ng of polyethylenimine per well. FlpIn CHO cells were maintained in DMEM media containing 10% FBS in a humidified incubator containing 5% CO2 at 37 C for 36 hr, followed by 12 hr of serum starvation prior to assaying. Radioligand saturation binding experiments were performed in binding buffer (10 mM HEPES pH 7.5, 145 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 2 mM CaCl 2 , 1.5 mM NaHCO 3 , 10 mM D-glucose) on whole FlpIn CHO cells grown in 96-well Iso-plates. After removal of cell media and a brief wash with binding buffer, cells were incubated in a final volume of 300 mL with different concentrations of [ 3 H] DPCPX for 3 hr at 4 C. Radioligand was discarded, cells were washed twice with ice-cold phosphate buffer saline (PBS, 10 mM Na 2 HPO 4 ; 1.8 mM KH 2 PO 4 ; 137 mM NaCl; 2.7 mM KCl), and dissolved in 100 mL Ultima Gold scintillation liquid (PerkinElmer) followed by b-counting. Concentrations of [ 3 H]DPCPX used in the assay were determined by b-counting using MicroBeta LumiJET counter (PerkinElmer). After subtraction of the nonspecific binding, measured in the presence of 1 mM SLV320, from total, curves were fitted to the ''One site-specific binding'' equation in Prism 6.0 (GraphPad) yielding B max and K d values. To account for different transfection efficiencies, all data were normalized to B max of the A 1wt . For radioligand competition binding experiments, cells were incubated with different concentrations of competing ligands (DPCPX, DU172, NECA and R-PIA) in the presence of approximately 2 nM [ 3 H]DPCPX (precise concentrations in each experiment were determined by b-counting) for 3 hr at 4 C, followed by the same treatment as in saturation binding. Additional competition binding experiments were also performed to assess the effects of rationally designed mutations on the affinity of the antagonists DPCPX and ZM241385. For these latter experiments, A 1(wt) -, A 1(T270M) -, A 2A(wt) -, A 2A(M270T) -AR constructs were transiently transfected into FlpIn CHO cells as described above, and competition binding was performed in a final volume of 100 mL HEPES buffer (145 mM NaCl, 10 mM D-Glucose, 5 mM KCl, 1 mM MgSO 4 , 10 mM HEPES, 1.3 mM CaCl 2 , 15 mM NaHCO 3 , pH 7.4) in the absence or presence of approximately 1 nM [ 3 H]DPCPX or 1 nM [ 3 H]ZM241385 (precise concentrations in each experiment were determined by b-counting) and a range of concentrations of the competing ligands DPCPX or ZM241385 at 37 C for 1 hr. Cells were then treated as outlined in saturation binding. In all cases, competition binding data were normalized to radioligand binding values in the absence of competitors. Competition curves were fitted to the one-site competition binding equation in Prism 6.0 (GraphPad Software, San Diego, CA) yielding logK i values. One-way ANOVA (Dunnett's post hoc) or an unpaired t test, as appropriate, was used to determine significance by comparing the logK I value for each mutant receptor to the corresponding wildtype construct.
For functional ERK 1/2 phosphorylation assays, transiently transfected FlpIn CHO cells 12 hr post serum starvation were assayed as described previously (Baltos et al., 2016) . Briefly, cells were incubated with increasing concentrations of agonists (NECA or R-PIA) in DMEM media for 5 min (peak response) in a humidified incubator containing 5% CO 2 at 37 C. Reaction was rapidly terminated by removal of media and addition of 100 mL SureFire lysis buffer to each well followed by 10 min shaking at 20 C. For detection, lysate was mixed with activation buffer, reaction buffer, AlphaScreen acceptor beads and AlphaScreen donor beads (AlphaScreen SureFire ERK1/2 kit from PerkinElmer) at 80:20:120:1:1 (v/v/v/v/v) ratio in a 384-well Proxiplate. Plates were incubated in the dark at 37 C for 1.5 hr followed by measurement on an EnVision plate reader (PerkinElmer) using AlphaScreen settings. Data were baseline-corrected and normalized to the response of A 1wt caused by 10 mM NECA.
For functional cAMP accumulation assays, the FlpIn CHO cells stably expressing the human A 1 -AR and A 2A -AR were seeded into 96-well culture plates at a density of 2 3 10 4 cells/well in DMEM containing 10% FBS, 600 mg/mL hygromycin B and incubated in a humidified incubator at 37 C in 5% CO 2 overnight. The accumulation of cAMP was determined as described previously (Nguyen et al., 2016a) . Briefly, media was replaced with stimulation buffer (140 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO 4 , 0.2 mM Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 1.3 mM CaCl 2 , 5.6 mM D-glucose, 5 mM HEPES, 0.1% bovine serum albumin (BSA), and 10 mM rolipram, pH 7.45) and incubated at 37 C for 30 min. Cells were then exposed to antagonist (DU172, MIPS2712, MIPS2719) for 30 min. NECA concentration response curves were performed by the subsequent addition of increasing concentrations of NECA and 3 mM forskolin (A 1 -AR-FlpIn-CHO only) in a final volume of 100 mL for 30 min at 37 C. The reactions were terminated by the addition of 50 mL ice cold 100% ethanol. The lysis buffer (0.1% BSA, 0.3% tween-20, 5 mM HEPES, pH 7.45) was added to the cells after the compete evaporation of ethanol. Detection of cAMP was performed using LANCE cAMP 384 kits (PerkinElmer) following manufacture's protocol and fluorescence was measured with an EnVisionâ plate reader (PerkinElmer). Agonist concentration-response curves were normalized to the response mediated by 3 mM forskolin alone and buffer alone. All experiments were performed in duplicate.
For A 1 -AR-FlpIn CHO cells, the G i/o protein-mediated inhibition of cAMP accumulation was determined as described previously (Nguyen et al., 2016a) . Briefly, media was replaced with 70 mL stimulation buffer (140 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO 4 , 0.2 mM Na 2 HPO 4 , 0.44 mM KH 2 PO 4 , 1.3 mM CaCl 2 , 5.6 mM D-glucose, 5 mM HEPES, 0.1% bovine serum albumin (BSA), and 10 mM rolipram, pH 7.45) and incubated at 37 C for 30 min. Cells were incubated with 10 mL of increasing concentrations of each antagonist (DU172, MIPS2712, MIPS2719) for 30 min. Concentration response assays were performed by subsequent incubation of increasing concentration of NECA (10 mL) and 3 mM forskolin (10 mL) for an additional 30 min at 37 C. The reactions were terminated by the addition of 50 mL ice cold 100% ethanol. The lysis buffer (0.1% BSA, 0.3% tween-20, 5 mM HEPES, pH 7.45) was added to the cells after the compete evaporation of ethanol. Detection of cAMP was performed using LANCE cAMP 384 kits (PerkinElmer) following manufacture's protocol and fluorescence was measured with an EnVisionâ plate reader (PerkinElmer). Agonist concentration-response curves were normalized to the response mediated by 3 mM forskolin (0%) or buffer (100%) alone. All experiments were performed in duplicate.
For A 2A -AR-FlpIn CHO cells, the G s protein-mediated stimulation of cAMP accumulation was determined as described below. After the removal of media, cells were incubated with 80 mL stimulation buffer at 37 C for 30 min. Cells were then exposed to a 30 min incubation with increasing concentrations of each antagonist (10 mL), follow by a further 30 min incubation with increasing concentrations of NECA (10 mL). Termination of the reactions and detection of cAMP were performed as described above. Agonist concentration-response curves were normalized to the response mediated by 3 mM forskolin (100%) or buffer (0%) alone. All experiments were performed in duplicate.
All data were analyzed using GraphPad Prism 6.0.
Functional interaction studies between NECA and multiple concentrations of each antagonist in the cAMP assays were fit to the following competitive model (Motulsky and Christopoulos, 2004) : Where pEC 50 is the negative logarithm of the EC 50 of NECA (A) in the absence of antagonist (B). HillSlope is the slope of the agonist curve, S is the Schild slope, pA 2 is the negative logarithm of the molar concentration of antagonist necessary to shift the agonist EC 50 by a factor of two. The Schild slope parameter, S, was constrained to 1 and therefore the estimated pA 2 values for each antagonist are equal to the pK B (negative logarithm of the antagonist equilibrium dissociation constant).
Thermal stability assays
The A 1 -AR construct used for crystallization studies was expressed and purified as described above. The thermal stability assay protocol was adapted from Alexandov et al. (Alexandrov et al., 2008) . Purified receptor (0.2 mg) in 15 mL volume was incubated with 10 or 100 mM compounds for 1 hr at 20 C in 10xCMC buffer in black PCR plates (Bio-Rad) under 4 mL of silicone oil (Sigma). Then, 5 mL of N-[4-(7-diethylamino-4methyl-3-coumarinyl)phenyl]maleimide dye (CPM; Sapphire Bioscience) was added to a final concentration of 10 mM and incubated for additional 15 min at 20 C. After a brief spin, the plate was gradually heated from 20 to 80 C in 3 intervals using a PCR machine. Each temperature was held for 90 s followed by a rapid (30 s) fluorescence reading using an EnVision plate reader (PerkinElmer) with 380/470 nm excitation/emission filters. After subtraction of the internal CPM fluorescence, data points were fitted to Boltzmann sigmoidal equation in Prism 6.0 (GraphPad) and T m was defined as the halfway of the transition.
Docking of A 1 -AR antagonists and allosteric modulators
Docking of selective A 1 -AR antagonists (DPCPX, PSB36, rolofylline, SLV320, MIPS2712 and MIPS2719) and allosteric modulators (VCP171 and compound 13b) was performed using ICM version 3.8.0 (Molsoft L.L.C., La Jolla, CA) (Neves et al., 2012) . Docking was performed by global optimization of the flexible ligand in the receptor field (Totrov and Abagyan, 1997) . DU172 and non-receptor molecules were removed from the structure. The binding pocket was defined around DU172 in the A 1 -AR crystal structure or around ZM241385 in the A 2A -AR crystal structure (PDB: 4EIY). Maps were generated in a 0.5 Å grid size within a 42.4 3 35.2 3 40.2 Å box for the A 1 -AR and a 36.0 3 45.0 3 41.1 Å box for the A 2A -AR, encompassing the binding site and the extracellular region of the receptor. To ensure sufficient Monte Carlo sampling, docking ''thoroughness'' was set to 30. Other parameters were set as defaults. The docking procedure was repeated 5 times for each ligand, and the docking pose with the lowest ICM score was chosen. Subsequent molecular dynamics simulation was performed for the DPCPX$A 1 -AR complex.
Molecular Dynamics (MD) Simulations MD simulations of the DPCPX$A 1 -AR complex were carried out with the NAMD2.10 (Phillips et al., 2005) package using CHARMM TIP3P model for water, CHARMM27 (Mackerell et al., 2004) for protein, lipids and salt ions, and CHARMM General Force Field (CGenFF) version 3.0.1 for the ligand. Force field parameters for DPCPX were generated using CGenFF program version 1.0.0 (Vanommeslaeghe et al., 2010) . The BRIL on ICL3 was removed and the chain termini at the 211 and 220 positions were capped with neutral groups (N terminus acetyl and C terminus N-methylamide). All histidines were protonated on the epsilon nitrogen. The simulation system contained the A 1 -AR receptor, DPCPX, a lipid bilayer containing $220 palmitoyl oleoyl phosphatidyl chlorine (POPC) molecules generated using the membrane plugin of the VMD software (version 1.9.2) (Humphrey et al., 1996) , and $15800 water molecules. Sodium and chloride ions were added to neutralize the system, with extra NaCl added to reach a final concentration of 150 mM. The initial dimension of the system was 97 Å x 98 Å x 97 Å .
During the MD simulations, a 2 fs time step was used and full electrostatic interactions were computed every 6 fs. The particle mesh Ewald (PME) (Essmann et al., 1995) method was used to evaluate long-range electrostatics. Van der Waals and short-range electrostatic interactions were cut off at 12 Å . Langevin dynamics were used as a thermostat to maintain the temperature at a constant 310 K with a damping coefficient of 5 ps -1 . The Langevin piston Nosé -Hoover method was used to maintain pressure at 1atm, period 200 fs, decay 50fs. The SHAKE algorithm was used to constrain all bonds to hydrogen atoms. Coordinates were written to the output trajectory file every 10 ps.
The simulation was initiated with a 10000-step minimization, followed by 10ns equilibration of lipid tails while the receptor, ligand, lipid head groups, water, and ion molecules were fixed. The whole system was then subjected to a 10000-step minimization, followed by 10ns of equilibration with 10 kcal mol À1 Å À2 harmonic-position restraints applied to all heavy atoms of the receptor and the ligand.
Subsequently, the final unconstrained MD simulations was run for 104 ns. VMD version 1.9.2 was used for the visualization and analysis of the system. Molecular images were generated using PYMOL (Schrö dinger).
Chemistry 4-((3-(8-Cyclohexyl-2,6-dioxo-1-propyl-1,2,6,7-tetrahydro-3H-purin-3-yl)propyl)carbamoyl)benzenesulfonic acid (MIPS2712) DU172 (10.0 mg, 19.3 mmol) was dissolved in THF (1 ml) and a lithium hydroxide solution (0.25 M in water, 2 mL). The reaction mixture was stirred in a sealed microwave tube at room temperature for the duration of 16 hr. The reaction mixture was purified by preparative column chromatography. The title compound was obtained as a white solid (7 mg, 70% N-(3-(8-Cyclohexyl-2,6-dioxo-1-propyl-1,2,6,7-tetrahydro-3H-purin-3-yl)propyl)-4-(N,N-dimethylsulfamoyl) benzamide (MIPS2719) DU172 (10.0 mg, 19.3 mmol) was dissolved in a dimethylamine solution (2 M in THF, 3 mL). The reaction mixture was stirred in a sealed microwave tube at room temperature for the duration of 4 days. Then, the volatile components were removed under reduced pressure and the residue was purified by preparative column chromatography. The title compound was obtained as a white solid (8 mg, 76% 
Statistical Analysis
All measures of drug affinity or potency were estimated as negative logarithms. Statistical comparisons were performed in GraphPad Prism 6.0. using either an unpaired t test or a one way ANOVA, followed by a Dunnett's post-test, as indicated in the main text.
DATA AND SOFTWARE AVAILABILITY
The accession number for the coordinates and structures factors of the A1_DU172 complex reported in this paper is PDB: 5UEN.
Cell 168 
